Health and Healthcare

AbbVie : ABBV

All AbbVie Articles

587 Articles

Chris Lange | Apr 25, 2018 at 8:35 AM EDT

Short Sellers Grow More Selective on Major Pharma Stocks

The April 13 short interest data have been compared with the previous figures, and short interest moves in these selected…

Chris Lange | Apr 22, 2018 at 10:15 AM EDT

Eli Lilly, Amgen and More Big Pharma Earnings to Look For This Week

24/7 Wall St. has put together a preview of AbbVie, Eli Lilly and some of the other top pharma and…

Jon C. Ogg | Apr 17, 2018 at 11:35 AM EDT

Will a Recent Rheumatoid Arthritis Drug Approval See Rekindled Interest?

Rheumatoid arthritis is an autoimmune disease that attacks tissues within the joints, and it is a major target of U.S.…

Chris Lange | Apr 11, 2018 at 8:30 AM EDT

The Major Pharma Stocks That Are Making Short Sellers Sick

The March 29 short interest data have been compared with the previous figures, and short interest in most of these…

Chris Lange | Mar 27, 2018 at 8:45 AM EDT

Which Major Pharma Stocks Short Sellers Are Keen On

The March 15 short interest data have been compared with the previous figures, and short interest moves in these selected…

Chris Lange | Mar 26, 2018 at 4:08 PM EDT

Monday’s Biggest Winners and Losers in the S&P 500

Monday was an incredible day for the broad U.S. markets, with the Dow posting one of its top 3 performances,…

Chris Lange | Mar 24, 2018 at 8:25 AM EDT

How Analysts See AbbVie After the Big Disappointment

AbbVie shares took a big step back last week after the firm reported less than favorable results for its relapsed/refractory…

Jon C. Ogg | Mar 23, 2018 at 9:10 AM EDT

Top Analyst Upgrades and Downgrades: AbbVie, American Water, Carnival, Cisco, Darden, DexCom, Micron, Nike, Occidental Petroleum and More

The top analyst upgrades, downgrades and other research calls from Friday include AbbVie, American Water, Carnival, Cisco, Darden, DexCom, Micron…

Chris Lange | Mar 22, 2018 at 4:08 PM EDT

Thursday’s Biggest Winners and Losers in the S&P 500

Thursday was an absolute disaster for the broad U.S. markets. There didn’t seem to be anything positive about Thursday for…

Chris Lange | Mar 22, 2018 at 11:50 AM EDT

AbbVie Slides on Weak Midstage Results

AbbVie saw its shares pull back on Thursday after it reported less than favorable midstage results for its relapsed/refractory small…

Lee Jackson | Mar 19, 2018 at 10:05 AM EDT

Jefferies Adds Red-Hot Retail Stock to Franchise Picks List

Jefferies has made a big move by adding a top retail company to its well-respected Franchise Picks list of stocks…

Chris Lange | Mar 12, 2018 at 8:35 AM EDT

Major Pharma Sees Big Drop in Short Interest

The February 28 short interest data have been compared with the previous figures, and short interest in most of these…

Chris Lange | Feb 28, 2018 at 9:10 AM EST

Short Sellers Hike Bets in Major Pharma

The February 15 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical…

Lee Jackson | Feb 28, 2018 at 8:40 AM EST

Jefferies Has 5 Stocks to Buy That Should Raise Dividends and Earnings

These five stocks come with upward earnings revisions and the potential for rising dividends. They all make good sense for…

Jon C. Ogg | Feb 17, 2018 at 9:40 AM EST

13 Fresh Dividend Hikes and Stock Buybacks Too Big to Ignore

These were 13 stock buyback and dividend hike announcements from the week of February 16 that were simply too large…

1 … 20 21 22 23 24 … 40

AbbVie : ABBV

All AbbVie Articles

Short Sellers Grow More Selective on Major Pharma Stocks

Eli Lilly, Amgen and More Big Pharma Earnings to Look For This Week

Will a Recent Rheumatoid Arthritis Drug Approval See Rekindled Interest?

The Major Pharma Stocks That Are Making Short Sellers Sick

Which Major Pharma Stocks Short Sellers Are Keen On

Monday’s Biggest Winners and Losers in the S&P 500

How Analysts See AbbVie After the Big Disappointment

Top Analyst Upgrades and Downgrades: AbbVie, American Water, Carnival, Cisco, Darden, DexCom, Micron, Nike, Occidental Petroleum and More

Thursday’s Biggest Winners and Losers in the S&P 500

AbbVie Slides on Weak Midstage Results

Jefferies Adds Red-Hot Retail Stock to Franchise Picks List

Major Pharma Sees Big Drop in Short Interest

Short Sellers Hike Bets in Major Pharma

Jefferies Has 5 Stocks to Buy That Should Raise Dividends and Earnings

13 Fresh Dividend Hikes and Stock Buybacks Too Big to Ignore

66-Year-Old Couple With $2.2M Thought They Were Frugal — Until They Audited Their Spending

SETM Is Up 27% YTD and 150% Over a Year. The S&P 500? Not Even Close.

A 61-Year-Old Widow Claimed Survivor Benefits While Still Working, Then the Earnings Test Triggered a $1-for-$2 Clawback

66-Year-Old Couple With $2.2M Thought They Were Frugal — Until They Audited Their Spending

A 61-Year-Old Widow Claimed Survivor Benefits While Still Working, Then the Earnings Test Triggered a $1-for-$2 Clawback

66-Year-Old Couple With $2.2M Thought They Were Frugal — Until They Audited Their Spending

SETM Is Up 27% YTD and 150% Over a Year. The S&P 500? Not Even Close.

AbbVie : ABBV

All AbbVie Articles

Short Sellers Grow More Selective on Major Pharma Stocks

Eli Lilly, Amgen and More Big Pharma Earnings to Look For This Week

Will a Recent Rheumatoid Arthritis Drug Approval See Rekindled Interest?

The Major Pharma Stocks That Are Making Short Sellers Sick

Which Major Pharma Stocks Short Sellers Are Keen On

Monday’s Biggest Winners and Losers in the S&P 500

How Analysts See AbbVie After the Big Disappointment

Top Analyst Upgrades and Downgrades: AbbVie, American Water, Carnival, Cisco, Darden, DexCom, Micron, Nike, Occidental Petroleum and More

Thursday’s Biggest Winners and Losers in the S&P 500

AbbVie Slides on Weak Midstage Results

Jefferies Adds Red-Hot Retail Stock to Franchise Picks List

Major Pharma Sees Big Drop in Short Interest

Short Sellers Hike Bets in Major Pharma

Jefferies Has 5 Stocks to Buy That Should Raise Dividends and Earnings

13 Fresh Dividend Hikes and Stock Buybacks Too Big to Ignore

66-Year-Old Couple With $2.2M Thought They Were Frugal — Until They Audited Their Spending

SETM Is Up 27% YTD and 150% Over a Year. The S&P 500? Not Even Close.

A 61-Year-Old Widow Claimed Survivor Benefits While Still Working, Then the Earnings Test Triggered a $1-for-$2 Clawback

Featured Reads

66-Year-Old Couple With $2.2M Thought They Were Frugal — Until They Audited Their Spending

A 61-Year-Old Widow Claimed Survivor Benefits While Still Working, Then the Earnings Test Triggered a $1-for-$2 Clawback